Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jong-Mu Sun

Showing results (251-260 of 303) with videos related to

Pageof 31
Sort By:
Cancer Research and Treatment|June 20, 2018
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent ChemoradiotherapySong Ee Park, Jae Myoung Noh, You Jin Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2025
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter TrialSehhoon Park, Hee Kyung Ahn, Seoyoung Lee, et al.
Cancer Research and Treatment|July 13, 2010
Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapyJina Yun, Kyoung-Mee Kim, Seung Tae Kim, et al.
Human Genetics|August 26, 2011
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populationsMyung-Ju Ahn, Hong-Hee Won, Jeeyun Lee, et al.
Clinical Lung Cancer|July 4, 2017
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor SamplesJong Ho Cho, Steffen Filskov Sorensen, Yoon-La Choi, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Journal of Pathology and Translational Medicine|March 27, 2018
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)Bo Mi Ku, Mi Hwa Heo, Joo-Hang Kim, et al.
Cancer|January 20, 2017
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)Youjin Kim, Su Jin Lee, Ji Yun Lee, et al.
The Oncologist|May 30, 2024
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancerWasat Mansoor, Seongjung Joo, Josephine M Norquist, et al.
Iscience|November 7, 2022
Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinomaHyoung-Oh Jeong, Hayoon Lee, Hyemin Kim, et al.
Pageof 31

Showing results (251-260 of 303) with videos related to

Sort By:
Pageof 31
Cancer Research and Treatment|June 20, 2018
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent ChemoradiotherapySong Ee Park, Jae Myoung Noh, You Jin Kim, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 11, 2025
Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter TrialSehhoon Park, Hee Kyung Ahn, Seoyoung Lee, et al.
Cancer Research and Treatment|July 13, 2010
Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapyJina Yun, Kyoung-Mee Kim, Seung Tae Kim, et al.
Human Genetics|August 26, 2011
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populationsMyung-Ju Ahn, Hong-Hee Won, Jeeyun Lee, et al.
Clinical Lung Cancer|July 4, 2017
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor SamplesJong Ho Cho, Steffen Filskov Sorensen, Yoon-La Choi, et al.
The Lancet. Oncology|December 25, 2025
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trialJong-Mu Sun, Yee Chao, Sung-Bae Kim, et al.
Journal of Pathology and Translational Medicine|March 27, 2018
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)Bo Mi Ku, Mi Hwa Heo, Joo-Hang Kim, et al.
Cancer|January 20, 2017
Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01)Youjin Kim, Su Jin Lee, Ji Yun Lee, et al.
The Oncologist|May 30, 2024
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancerWasat Mansoor, Seongjung Joo, Josephine M Norquist, et al.
Iscience|November 7, 2022
Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinomaHyoung-Oh Jeong, Hayoon Lee, Hyemin Kim, et al.
Pageof 31